2025 CGT Trends & Innovations: In Vivo Advancements, Non-Oncology Focus, and Manufacturing Breakthroughs
Cell & Gene
The most valuable resource for professionals who make their living in the cell & gene therapies industry.
TRENDING CONTENT - Catch Up
We catch up with Dr. Konstantin Konstantinov , CTO at Ring Therapeutics , and Ryan Crisman , Ph.D., cofounder and CTO at Umoja Biopharma , to get their thoughts on the future of new anellovirus vectors and existing lentiviral vector technology for in vivo gene delivery respectively.
Leaders from Kiji Therapeutics , Precision BioSciences, Inc. , and Orgenesis Inc. weigh in on what will likely accelerate the development of novel treatments, potentially revolutionizing patient care across a wider range of diseases and bringing the promise of personalized medicine closer to reality in 2025 and beyond.
We break down three trends driving development in cell therapy in 2024.
Business leaders can enhance QC operations by adopting a holistic view of the quality ecosystem and embracing comprehensive modernization strategies. Explore four principles for greater QC lab agility.
Manufacturing chimeric antigen receptor (CAR) T-cell therapies is a costly and complicated process. Interius BioTherapeutics is on a mission to reduce this complexity and get these therapies to patients faster — by manufacturing CAR T/NK cells in patients' bodies.
Through this workshop, participants will gain insights into the development and evaluation of ADCs, from preclinical research to manufacturing intricacies (CMC) and clinical advancements.
领英推荐
CELL & GENE: THE PODCAST - Listen Here
“How do you make this product consistently, how do you have control, when you’re making thousands, tens of thousands of these cell therapy products?” Roswell Park Comprehensive Cancer Center ’s Dr. Christopher Choi joins #CellAndGenePodcast to discuss the role of automation in CGT manufacturing.
CELL & GENE LIVE! - Register Now
2025 CGT Regulatory Outlook
Thursday, January 16, 2025 11:00 AM Eastern Standard Time 1 hour
As the cell and gene therapy landscape continues to rapidly evolve, with over 450 unique products in clinical development and 50 approvals expected by 2030, understanding the regulatory environment is crucial for stakeholders across the industry. Our upcoming Cell & Gene Live focuses on the forward-looking perspectives on the regulatory landscape that will shape the future of cell and gene therapies.
Join industry experts Kimberly Benton , Ph.D., and Bambi Grilley, RPh, CIP, CCRC, CCRP, RAC for an engaging virtual discussion on key regulatory challenges and opportunities in the coming year, potential changes in FDA approval processes for cell and gene therapies, strategies for navigating complex regulatory frameworks, the impact of recent regulatory developments on clinical trials and manufacturing, and more. Registration is free.?